Loading...
Market
Will CagriSema achieve target weight loss in future Phase 3 trial by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Novo Nordisk official press releases and clinical trial results publications
Story
Novo Nordisk Shares Drop 27% as CagriSema Misses Weight Loss Target in Phase 3 Trial
Dec 20, 2024, 11:00 AM
Novo Nordisk, Europe's largest company, saw its shares plummet by up to 27%, marking its worst trading day since April 2002, after its experimental obesity drug CagriSema failed to meet weight loss expectations in the Phase 3 REDEFINE 1 trial. The trial showed that patients treated with CagriSema achieved a 22.7% weight reduction after 68 weeks, falling short of the anticipated 25%. Additionally, only 57% of patients reached the highest dose after 68 weeks. Comparatively, patients receiving semaglutide 2.4 mg and cagrilintide 2.4 mg experienced weight losses of 16.1% and 11.8%, respectively, while the placebo group lost 2.3%. The disappointing results led to a significant sell-off, with the stock losing its 200-day moving average at $125 and trading 48% below its June high. Competitors such as Eli Lilly and Viking Therapeutics saw their shares rise in response to the news.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 22.7% • 25%
22.7% to 24.9% • 25%
25% to 27% • 25%
More than 27% • 25%
Achieve target weight loss in all regions • 25%
Achieve target weight loss in some regions • 25%
No region achieves target weight loss • 25%
Trials discontinued • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%